Consistent with this survey result, our study revealed that therapeutic G-CSF, which is not recommended by the clinical practice guidelines in Japan, was also used in many EBC patients with FNH, suggesting the need of education for oncologists involved in breast cancer treatment in Japan. The gene discussed is CSF3; the disease is breast carcinoma.